<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36042248</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset.</ArticleTitle><Pagination><StartPage>14739</StartPage><MedlinePgn>14739</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14739</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-18942-x</ELocationID><Abstract><AbstractText>Neurofilament heavy (NEFH) is one of the critical proteins required for the formation of the neuronal cytoskeleton and polymorphisms in NEFH are reported as a rare cause of sporadic ALS (sALS). In the current study, a candidate tetranucleotide (TTTA) repeat variant in NEFH was selected using an in-silico short structural variant (SSV) evaluation algorithm and investigated in two cohorts of North American sALS patients, both separately and combined (Duke cohort n&#x2009;=&#x2009;138, Coriell cohort n&#x2009;=&#x2009;333; combined cohort n&#x2009;=&#x2009;471), compared to a group of healthy controls from the Coriell Institute biobank (n&#x2009;=&#x2009;496). Stratification according to site of disease onset revealed that the 9 TTTA allele was associated with reduced disease risk, specifically confined to spinal-onset sALS patients in the Duke cohort (p&#x2009;=&#x2009;0.001). Furthermore, carriage of the 10 TTTA allele was associated with a 2.7&#xa0;year later age of disease onset in the larger combined sALS cohort (p&#x2009;=&#x2009;0.02). These results suggest that the 9 and 10 TTTA motif length may have a protective advantage for potentially lowering the risk of sALS and delaying the age of disease onset, however, these results need to be replicated in larger multicenter and multi-ethnic cohorts.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theunissen</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderton</LastName><ForeName>Ryan S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health Sciences and Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastaglia</LastName><ForeName>Frank L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkari</LastName><ForeName>P Anthony</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, First floor, RR block, QEII Medical Centre, 8 Verdun St, Nedlands, WA, 6009, Australia. Anthony.akkari@perron.uwa.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia. Anthony.akkari@perron.uwa.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, Australia. Anthony.akkari@perron.uwa.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA. Anthony.akkari@perron.uwa.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>108688-71-7</RegistryNumber><NameOfSubstance UI="C051774">neurofilament protein H</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36042248</ArticleId><ArticleId IdType="pmc">PMC9427846</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-18942-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-18942-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott D, Smith KE, O'Brien BJ, Angelides KJ. Characterization of mammalian neurofilament triplet proteins. Subunit stoichiometry and morphology of native and reconstituted filaments. J. Biol. Chem. 1985;260:10736&#x2013;10747. doi: 10.1016/S0021-9258(19)85144-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)85144-X</ArticleId><ArticleId IdType="pubmed">2993286</ArticleId></ArticleIdList></Reference><Reference><Citation>Straube-West K, Loomis PA, Opal P, Goldman RD. Alterations in neural intermediate filament organization: functional implications and the induction of pathological changes related to motor neuron disease. J. Cell Sci. 1996;109:2319&#x2013;2329. doi: 10.1242/jcs.109.9.2319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.109.9.2319</ArticleId><ArticleId IdType="pubmed">8886982</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, et al. New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis. Transl. Neurodegener. 2021;10:1&#x2013;16. doi: 10.1186/s40035-021-00272-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00272-z</ArticleId><ArticleId IdType="pmc">PMC8597313</ArticleId><ArticleId IdType="pubmed">34789332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner OI, et al. Mechanisms of mitochondria-neurofilament interactions. J. Neurosci. 2003;23:9046&#x2013;9058. doi: 10.1523/JNEUROSCI.23-27-09046.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-27-09046.2003</ArticleId><ArticleId IdType="pmc">PMC6740819</ArticleId><ArticleId IdType="pubmed">14534238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol. Neurodegener. 2020;15:58. doi: 10.1186/s13024-020-00406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00406-3</ArticleId><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, Donnenfeld H, Sasaki S, Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1984;43:461&#x2013;470. doi: 10.1097/00005072-198409000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198409000-00001</ArticleId><ArticleId IdType="pubmed">6540799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, et al. Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. Acta Neuropathol. 1990;79:402&#x2013;408. doi: 10.1007/BF00308716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308716</ArticleId><ArticleId IdType="pubmed">2111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh T, et al. Phosphorylated high molecular weight neurofilament protein in the peripheral motor, sensory and sympathetic neuronal perikarya: system-dependent normal variations and changes in amyotrophic lateral sclerosis and multiple system atrophy. Acta Neuropathol. 1992;83:240&#x2013;245. doi: 10.1007/BF00296785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00296785</ArticleId><ArticleId IdType="pubmed">1557955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sihag RK, Inagaki M, Yamaguchi T, Shea TB, Pant HC. Role of phosphorylation on the structural dynamics and function of types III and IV intermediate filaments. Exp. Cell Res. 2007;313:2098&#x2013;2109. doi: 10.1016/j.yexcr.2007.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2007.04.010</ArticleId><ArticleId IdType="pmc">PMC2570114</ArticleId><ArticleId IdType="pubmed">17498690</ArticleId></ArticleIdList></Reference><Reference><Citation>Didonna A, Opal P. The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders. Mol. Neurodegener. 2019;14:19. doi: 10.1186/s13024-019-0318-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0318-4</ArticleId><ArticleId IdType="pmc">PMC6524292</ArticleId><ArticleId IdType="pubmed">31097008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant HC. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem. J. 1988;256:665&#x2013;668. doi: 10.1042/bj2560665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2560665</ArticleId><ArticleId IdType="pmc">PMC1135461</ArticleId><ArticleId IdType="pubmed">2851997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge W-W, Leystra-Lantz C, Wen W, Strong MJ. Selective loss of trans-acting instability determinants of neurofilament mRNA in amyotrophic lateral sclerosis spinal cord. J. Biol. Chem. 2003;278:26558&#x2013;26563. doi: 10.1074/jbc.M302886200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302886200</ArticleId><ArticleId IdType="pubmed">12730211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron C, et al. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. J. Neuropathol. Exp. Neurol. 1994;53:221&#x2013;230. doi: 10.1097/00005072-199405000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199405000-00002</ArticleId><ArticleId IdType="pubmed">7909836</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies FM, et al. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J. Neurochem. 2002;82:1118&#x2013;1128. doi: 10.1046/j.1471-4159.2002.01045.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01045.x</ArticleId><ArticleId IdType="pubmed">12358759</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Leystra-Lantz C, Ge W-W. Intermediate filament steady-state mRNA levels in amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2004;316:317&#x2013;322. doi: 10.1016/j.bbrc.2004.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.02.051</ArticleId><ArticleId IdType="pubmed">15020220</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley ZCE, Campos-Melo D, Strong MJ. MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS) Brain Res. 2019;1706:93&#x2013;100. doi: 10.1016/j.brainres.2018.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.10.032</ArticleId><ArticleId IdType="pubmed">30385300</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Melo D, Hawley ZCE, Strong MJ. Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs. Mol. Brain. 2018;11:43. doi: 10.1186/s13041-018-0386-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-018-0386-3</ArticleId><ArticleId IdType="pmc">PMC6054723</ArticleId><ArticleId IdType="pubmed">30029677</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ. Neurofilament metabolism in sporadic amyotrophic lateral sclerosis. J. Neurol Sci. 1999;169:170&#x2013;177. doi: 10.1016/S0022-510X(99)00241-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00241-5</ArticleId><ArticleId IdType="pubmed">10540027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong NKY, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS) J. Neuropathol. Exp. Neurol. 2000;59:972&#x2013;982. doi: 10.1093/jnen/59.11.972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.11.972</ArticleId><ArticleId IdType="pubmed">11089575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, et al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J. Neurochem. 2018;146:631&#x2013;641. doi: 10.1111/jnc.14542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14542</ArticleId><ArticleId IdType="pmc">PMC6175430</ArticleId><ArticleId IdType="pubmed">29959860</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 1994;3:1757&#x2013;1761. doi: 10.1093/hmg/3.10.1757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/3.10.1757</ArticleId><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Rouleau GA, Krizus A, Julien J-P. Polymorphism in the multi-phosphorylation domain of the human neurofilament heavy-subunit-encoding gene. Gene. 1993;132:297&#x2013;300. doi: 10.1016/0378-1119(93)90211-K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(93)90211-K</ArticleId><ArticleId IdType="pubmed">8224877</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Human Mol. Genet. 1999;8:157&#x2013;164. doi: 10.1093/hmg/8.2.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.2.157</ArticleId><ArticleId IdType="pubmed">9931323</ArticleId></ArticleIdList></Reference><Reference><Citation>Skvortsova V, et al. Analysis of heavy neurofilament subunit gene polymorphism in Russian patients with sporadic motor neuron disease (MND) Eur. J. Hum. Genet. 2004;12:241&#x2013;244. doi: 10.1038/sj.ejhg.5201144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5201144</ArticleId><ArticleId IdType="pubmed">14722583</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripolszki K, et al. Comprehensive genetic analysis of a Hungarian amyotrophic lateral sclerosis cohort. Front. Genet. 2019;10:732. doi: 10.3389/fgene.2019.00732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2019.00732</ArticleId><ArticleId IdType="pmc">PMC6707335</ArticleId><ArticleId IdType="pubmed">31475037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomkins J, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS) NeuroReport. 1998;9:3967&#x2013;3970. doi: 10.1097/00001756-199812010-00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199812010-00036</ArticleId><ArticleId IdType="pubmed">9875737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F, et al. Sequencing of neurofilament genes identified NEFH Ser787Arg as a novel risk variant of sporadic amyotrophic lateral sclerosis in Chinese subjects. BMC Med. Genomics. 2021;14:222. doi: 10.1186/s12920-021-01073-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-021-01073-z</ArticleId><ArticleId IdType="pmc">PMC8436554</ArticleId><ArticleId IdType="pubmed">34511133</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Miller CCJ. Neurofilaments and neurological disease. BioEssays. 2003;25:346&#x2013;355. doi: 10.1002/bies.10251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.10251</ArticleId><ArticleId IdType="pubmed">12655642</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, et al. Structural variants may be a source of missing heritability in sALS. Front. Neurosci. 2020;14:47. doi: 10.3389/fnins.2020.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00047</ArticleId><ArticleId IdType="pmc">PMC7005198</ArticleId><ArticleId IdType="pubmed">32082115</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Flynn LL, Anderton RS, Akkari PA. Short structural variants as informative genetic markers for ALS disease risk and progression. BMC Med. 2022;20:11. doi: 10.1186/s12916-021-02206-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02206-y</ArticleId><ArticleId IdType="pmc">PMC8762977</ArticleId><ArticleId IdType="pubmed">35034660</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul R, Lutz MW, Burns DK, Roses AD, Chiba-Falek O. The SSV evaluation system: a tool to prioritize short structural variants for studies of possible regulatory and causal variants. Hum. Mutat. 2016;37:877&#x2013;883. doi: 10.1002/humu.23023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23023</ArticleId><ArticleId IdType="pmc">PMC4983215</ArticleId><ArticleId IdType="pubmed">27279261</ArticleId></ArticleIdList></Reference><Reference><Citation>El Brooks BR. Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 1994;124:96&#x2013;107. doi: 10.1016/0022-510X(94)90191-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, et al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front. Aging Neurosci. 2021;13:127. doi: 10.3389/fnagi.2021.658226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.658226</ArticleId><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pytte J, et al. Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis. Neurol. Genet. 2020;6:e406. doi: 10.1212/NXG.0000000000000406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000406</ArticleId><ArticleId IdType="pmc">PMC7061286</ArticleId><ArticleId IdType="pubmed">32185242</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Khleifat A, et al. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom. Med. 2021;7:8. doi: 10.1038/s41525-021-00267-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-021-00267-9</ArticleId><ArticleId IdType="pmc">PMC8799638</ArticleId><ArticleId IdType="pubmed">35091648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, et al. Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature. Int. J. Mol Sci. 2019;20:4152. doi: 10.3390/ijms20174152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20174152</ArticleId><ArticleId IdType="pmc">PMC6747516</ArticleId><ArticleId IdType="pubmed">31450699</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, et al. Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives. Neural Regen. Res. 2021;16:1985. doi: 10.4103/1673-5374.308072.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.308072</ArticleId><ArticleId IdType="pmc">PMC8343335</ArticleId><ArticleId IdType="pubmed">33642372</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol. Neurosurg. Psychiatry. 2022;93:68&#x2013;74. doi: 10.1136/jnnp-2021-327129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327129</ArticleId><ArticleId IdType="pubmed">34417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2018;89:367&#x2013;373. doi: 10.1136/jnnp-2017-316605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302. doi: 10.1212/WNL.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, et al. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J. Neurol. 2020;267:2272&#x2013;2280. doi: 10.1007/s00415-020-09838-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09838-9</ArticleId><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="pubmed">32306171</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol. Neurosurg. Psychiatry. 2021;92:510&#x2013;518. doi: 10.1136/jnnp-2020-325014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465. doi: 10.1016/S1474-4422(21)00414-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Advances in the genetic classification of ALS. Curr. Opin. Neurol. 2021;34:756. doi: 10.1097/WCO.0000000000000986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000986</ArticleId><ArticleId IdType="pmc">PMC7612116</ArticleId><ArticleId IdType="pubmed">34343141</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240. doi: 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>